DRUG STUDY

Generic Name
(Brand Name)
Indication Dosage, Route,
Frequency
Mechanism of
Action
Adverse Reaction Contraindication Nursing
Responsibility

Methylergonovine
maleate

Methergine

Methylergobasine

Methylergobrevin

Methylergonovine)

Prevention and
treatment of
postpartum and
postabortion
hemorrhage
caused by uterine
atony or
subinvolution

2 Ampules
immediately after
the delivery of
the Placenta

Methergine

Stimulates
uterine smooth
muscles

producing
sustained
contractions

thereby shortens
the third stage of
labor


Cardiovascular:
hypertension,
temporary chest
pain, palpitation
CNS:Hallucinations,
dizziness, seizure,
headache
Gastrointestinal:
Nausea, vomiting,
diarrhea, foul taste
Local:
Thrombophlebitis
Otic: Tinnitus
Renal: Hematuria
Respiratory:
Dyspnea, nasal
congestion


> contraindicated
in patients
hypersensitive to
methylergonovine
or any component
of the
formulation.
>ergot alkaloids
are
contraindicated
with potent
inhibitors of
CYP3A4 (includes
protease
inhibitors, azole
antifungals, and
some macrolide
antibiotics);
>hypertension;
toxemia of
pregnancy (PIH)


>Be alert for
adverse reactions
and drug
interactions.
>This drug should
be used extremely
carefully because
of it's potent
vasoconstrictor
action. I.V. use
may induce
sudden
hypertension and
cerebrovascular
accidents. As a
last resort, give
I.V. slowly over
several minutes
and monitor
blood pressure
closely.
>Monitor Uterine
Contractions

Generic Name
(Brand Name)
Indication Dosage, Route,
Frequency
Mechanism of
Action
Adverse Reaction Contraindication Nursing
Responsibility



Oxytocin

(Syntocinon)




Induction of labor
at term; control of
postpartum
bleeding;
adjunctive therapy
in management of
abortion





10 units/ml in
1ml ampule, vial
or syringe in
compatible IV
solution.





to induce or milk
ejection and
stimulate
contraction



Hypersensitive
to drug when
vaginal delivery
is advised

- cephalopelvic
disproportion is
present

-when delivery
requires
conversion as in
transverse lie


CV:
Hypertension,
increased heart
rate, systemic
venous return,
cardiac output

GI: Nausea,
vomiting

RESPIRATORY:
Anoxia, asphyxia

OTHERS:
Low APGAR
score at 5 mins.


Continuously
monitor
contractions,
fetal and
maternal
heart rate, and
maternal
blood
pressure and
ECG.
Discontinue
infusion if
uterine
hyperactivity
occurs.

Monitor
patient
extremely
closely during
first and
second stages
of labor
because of risk
of cervical
laceration,
uterine
rupture and
maternal and
fetal death.